CPIC

Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Y. Saito, L. K. Stamp, K. E. Caudle, M. S. Hershfield, E. M. McDonagh, John Callaghan, W. Tassaneeyakul, T. Mushiroda, N. Kamatani, B. R. Goldspiel, E. J. Phillips, T. E. Klein, M. T M Lee

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B 58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)36-37
Number of pages2
JournalClinical Pharmacology and Therapeutics
Volume99
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Pharmacogenetics
Guidelines
Research
Allopurinol
HLA-B Antigens
Electronic Health Records
Publications
Genotype
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

CPIC : Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. / Saito, Y.; Stamp, L. K.; Caudle, K. E.; Hershfield, M. S.; McDonagh, E. M.; Callaghan, John; Tassaneeyakul, W.; Mushiroda, T.; Kamatani, N.; Goldspiel, B. R.; Phillips, E. J.; Klein, T. E.; Lee, M. T M.

In: Clinical Pharmacology and Therapeutics, Vol. 99, No. 1, 01.01.2016, p. 36-37.

Research output: Contribution to journalArticle

Saito, Y, Stamp, LK, Caudle, KE, Hershfield, MS, McDonagh, EM, Callaghan, J, Tassaneeyakul, W, Mushiroda, T, Kamatani, N, Goldspiel, BR, Phillips, EJ, Klein, TE & Lee, MTM 2016, 'CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network', Clinical Pharmacology and Therapeutics, vol. 99, no. 1, pp. 36-37. https://doi.org/10.1002/cpt.161
Saito, Y. ; Stamp, L. K. ; Caudle, K. E. ; Hershfield, M. S. ; McDonagh, E. M. ; Callaghan, John ; Tassaneeyakul, W. ; Mushiroda, T. ; Kamatani, N. ; Goldspiel, B. R. ; Phillips, E. J. ; Klein, T. E. ; Lee, M. T M. / CPIC : Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. In: Clinical Pharmacology and Therapeutics. 2016 ; Vol. 99, No. 1. pp. 36-37.
@article{d0fa8b166c1d4b9b879d9602a4d66abf,
title = "CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network",
abstract = "The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B 58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).",
author = "Y. Saito and Stamp, {L. K.} and Caudle, {K. E.} and Hershfield, {M. S.} and McDonagh, {E. M.} and John Callaghan and W. Tassaneeyakul and T. Mushiroda and N. Kamatani and Goldspiel, {B. R.} and Phillips, {E. J.} and Klein, {T. E.} and Lee, {M. T M}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/cpt.161",
language = "English (US)",
volume = "99",
pages = "36--37",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - CPIC

T2 - Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

AU - Saito, Y.

AU - Stamp, L. K.

AU - Caudle, K. E.

AU - Hershfield, M. S.

AU - McDonagh, E. M.

AU - Callaghan, John

AU - Tassaneeyakul, W.

AU - Mushiroda, T.

AU - Kamatani, N.

AU - Goldspiel, B. R.

AU - Phillips, E. J.

AU - Klein, T. E.

AU - Lee, M. T M

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B 58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

AB - The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B 58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

UR - http://www.scopus.com/inward/record.url?scp=84955325490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955325490&partnerID=8YFLogxK

U2 - 10.1002/cpt.161

DO - 10.1002/cpt.161

M3 - Article

VL - 99

SP - 36

EP - 37

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -